Please assess the completion status of the following clinical trial:

Trial Title: Treprostinil Combined With Tadalafil for Pulmonary Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients 18-80 years of age~2. World Health Organization Group 1 PAH~   1. Idiopathic PAH~  2. Heritable PAH~  3. PAH associated with connective tissue disease~  4. PAH associated with surgical repair of congenital left to right shunt~  5. PAH associated with anorectic drug use~3. WHO functional Class III-IV~4. 6 minute walking distance \> 150-meters and \< 450 meters~5. Right heart catheterization showing mean PAP (pulmonary arterial pressure)\> 25 mmHg and PCWP (pulmonary capillary wedge pressure) \< 15 mmHg within 6 months of study entry.~Exclusion Criteria:~1. Pulmonary hypertension associated with~   a. Portal hypertension b. HIV infection c. Pulmonary venous hypertension defined as PCWP \> 15 mmHg d. Chronic lung disease defined as i. FEV1(forced expiratory volume at one second~   )/FVC (forced vital capacity) less than 0.65 ii. TLC \< 0.70 iii. Untreated Sleep Apnea with AHI (apnea-hypopnea index )\> 20 or hemoglobin oxygen saturation nadir \< 87% e. Chronic Thromboembolic Disease f. Sarcoidosis g. Pulmonary veno occlusive disease (PVOD)~2. Concomitant use of nitrates (any form) either regularly or intermittently.~3. Concomitant use of potent CYP3A inhibitors (e.g., ritonavir, ketoconazole, itraconazole)~4. Vascular disease of the retina including retinitis pigmentosa, any sudden vision loss, including any damage to the optic nerve or NAION~5. low blood pressure or high blood pressure that is not controlled~6. Postural hypotension~7. Inability to manage home infusion therapy~8. Pulmonary vasodilator therapy with any phosphodiesterase inhibitor or endothelin receptor antagonist within 30 days of study entry~9. Participation in a clinical investigational study within previous 30 days~10. Renal failure defined as:~    1. estimated creatinine clearance \< 30 ml/min~   2. serum creatinine \> 2.5 mg/dl~11. Subjects with liver function abnormalities (ALT \[Alanine Aminotransferase or AST (Alanine Aminotransferase ) \> 3 times the upper limit of normal at screening or at baseline) or chronic liver disease~12. History of hypersensitivity reaction or adverse effect related to tadalafil~13. Life expectancy \< 12 months~14. History of deformed penis shape, an erection that lasted more than 4 hours, or Peyronie's disease.~15. Blood cell problems such as sickle cell anemia, multiple myeloma, or leukemia~16. Pregnant or planning to become pregnant or breast feed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tadalafil (Type: ACTIVE_COMPARATOR): first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort
- Placebo (Type: PLACEBO_COMPARATOR): first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).